Although in animal models of the disease several drugs acting on 5-HT1A/1C or 5-HT1B receptors decrease the expression of L-DOPA-induced dyskinesia (Miguelez et al., 2013), translational extrapolation to the clinic has been less positive. This evidence concerns the gene HTR1A and drug-induced dyskinesia.